Cara Therapeutics Changes Business Address to 400 Atlantic St, Stamford
Ticker: TVRD · Form: 8-K · Filed: Feb 2, 2024 · CIK: 1346830
| Field | Detail |
|---|---|
| Company | Cara Therapeutics, Inc. (TVRD) |
| Form Type | 8-K |
| Filed Date | Feb 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance
TL;DR
**Cara Therapeutics moved offices, no big deal for investors.**
AI Summary
Cara Therapeutics, Inc. filed an 8-K on February 2, 2024, to report a change in its business address. The company's principal executive offices moved from 4 Stamford Plaza, 107 Elm Street, 9th Floor, Stamford, Connecticut 06902 to 400 Atlantic Street, Suite 500, Stamford, Connecticut 06901, effective February 1, 2024. This administrative change is minor and does not indicate any operational or financial shifts, so it has minimal impact on current or prospective shareholders.
Why It Matters
This filing is purely administrative, reporting a change of address for Cara Therapeutics. It has no direct impact on the company's financial performance, operations, or stock value.
Risk Assessment
Risk Level: low — The filing reports a routine administrative change (a new business address) and does not indicate any financial or operational risks.
Analyst Insight
This filing is purely administrative and does not provide any actionable insights for investment decisions. Investors should focus on operational and financial reports for Cara Therapeutics.
Key Players & Entities
- Cara Therapeutics, Inc. (company) — the registrant filing the 8-K
- February 1, 2024 (date) — date of earliest event reported (address change)
- 400 Atlantic Street, Suite 500, Stamford, Connecticut 06901 (address) — new principal executive offices
- 4 Stamford Plaza, 107 Elm Street, 9th Floor, Stamford, Connecticut 06902 (address) — former principal executive offices
FAQ
What is the primary purpose of this 8-K filing by Cara Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report a change in the business address of Cara Therapeutics, Inc., effective February 1, 2024.
What was Cara Therapeutics, Inc.'s former business address?
Cara Therapeutics, Inc.'s former business address was 4 Stamford Plaza, 107 Elm Street, 9th Floor, Stamford, Connecticut 06902.
What is Cara Therapeutics, Inc.'s new business address?
Cara Therapeutics, Inc.'s new business address is 400 Atlantic Street, Suite 500, Stamford, Connecticut 06901.
When did the change in business address become effective?
The change in business address became effective on February 1, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.
Does this 8-K filing indicate any changes in Cara Therapeutics, Inc.'s financial performance or operations?
No, this 8-K filing solely reports an administrative change of the company's principal executive offices and does not indicate any changes in financial performance or operations.
Filing Stats: 701 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2024-02-02 16:59:57
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CARA The Nasdaq Stock Marke
- $1.00 — e Company's common stock has been below $1.00 per share for 30 consecutive business d
Filing Documents
- tm245054d1_8k.htm (8-K) — 27KB
- 0001104659-24-010123.txt ( ) — 242KB
- cara-20240201.xsd (EX-101.SCH) — 3KB
- cara-20240201_def.xml (EX-101.DEF) — 26KB
- cara-20240201_lab.xml (EX-101.LAB) — 36KB
- cara-20240201_pre.xml (EX-101.PRE) — 25KB
- tm245054d1_8k_htm.xml (XML) — 5KB
01
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 1, 2024, Cara Therapeutics, Inc. (the " Company ") received a notice from The Nasdaq Stock Market (" Nasdaq ") that the Company is not in compliance with Nasdaq's Listing Rule 5450(a)(1), as the minimum bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until July 30, 2024, to regain compliance with the minimum bid price requirement. To regain compliance, the minimum bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-calendar day grace period. In the event the Company does not regain compliance with the minimum bid price requirement by July 30, 2024, the Company may be eligible for an additional 180-calendar day compliance period if it elects to transfer to The Nasdaq Capital Market to take advantage of the additional compliance period offered on that market. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the bid price deficiency during the second compliance period. The Company's failure to regain compliance during this period could result in delisting. The Company intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the listing requirements. There can be no assurance that the Company will be able to regain compliance with Nasdaq's Listing Rule 5450(a)(1) or will otherwise be in complian
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARA THERAPEUTICS, INC. By: /s/ RYAN MAYNARD Ryan Maynard Chief Financial Officer (Principal Financial and Accounting Officer) Date: February 2, 2024